SIRION Biotech, a top viral vector platform company that is renowned for developing high quality viral vector solutions for academic and industry partners, recently announced that it intends to establish a new office in the Boston area.
SIRION has partnered with the Massachusetts Life Sciences Center (MLSC) to find an office and lab space, which is a crucial part of the company’s U.S. expansion.
“We appreciate the assistance from Massachusetts Life Sciences Center in helping us begin building our U.S. operations in the Boston area during such an exciting time in our industry,” SIRION Biotech Chief Operating Officer Dieter Lingelbach said. “We are a growing company, planning to build on the success we’ve had in Europe, Israel and Japan, as we collaborate with many companies pioneering gene therapies.”
Angus McQuilken, MLSC's vice president for communications and marketing, said the gene therapy space continues to receive significant attention from stakeholders in the life sciences due to its potential to cure a variety of diseases.
“Producing products of the highest quality, purity and yield are of paramount importance and is also one of the biggest challenges,” SIRION's founder and Chief Technical Officer Christian Thirion said. “Our suite of proprietary products and services enables us to provide the highest quality tools for downstream applications in gene therapy and vaccine development.”
Representatives made the announcement in Philadelphia at the 2015 BIO International Convention.